PCVX - Vaxcyte's pneumococcal shot shows safety profile comparable to Pfizer's Prevnar 20

2023-12-05 06:33:06 ET

Vaxcyte's ( NASDAQ: PCVX ) investigational 24-valent pneumococcal conjugate vaccine (PCV), VAX-24, has shown a safety and tolerability profile comparable to Pfizer's ( PFE ) Prevnar 20 shot for the prevention of invasive pneumococcal disease in healthy adults 18-64 years of age.

Results from a Phase 1/2 clinical proof-of-concept study , published in the journal The Lancet Infectious Diseases, suggests that VAX-24 demonstrated safety and tolerability results similar to PCV20, the current standard-of-care, across all ages and doses studied through six months.

Frequently reported local and systemic reactions were generally mild-to-moderate, resolving within several days of vaccination, with no meaningful difference observed across the cohorts.

The Vaxcyte vaccine also showed robust opsonophagocytic activity and immunoglobulin G immune responses for all 24 serotypes at all doses studied.

In particular, the VAX-24 2.2 mcg dose met or exceeded the established regulatory immunogenicity standards for all 24 serotypes and will hence advance into a Phase 3 clinical program, results from which are expected in 2025.

Last month, Merck's ( MRK ) pneumococcal shot showed superior immunogenicity in a late-stage trial, evaluating the vaccine against Pfizer's ( PFE ) PCV20 in adults 18 years of age and older who had not previously received a pneumococcal conjugate vaccine.

More on Vaxcyte

• Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling
• Vaxcyte teams up with Lonza to make pneumococcal conjugate vaccines
• Seeking Alpha’s Quant Rating on Vaxcyte
• Historical earnings data for Vaxcyte
• Financial information for Vaxcyte

For further details see: